First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience

Wilms’ tumor 1 (WT1) protein is highly immunogenic and overexpressed in acute myeloid leukemia (AML), consequently ranked as a promising target for novel immunotherapeutic strategies. Here we report our experience of a phase I/II clinical trial (NCT01051063) of a vaccination strategy based on WT1 re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreutmair, Stefanie, Pfeifer, Dietmar, Waterhouse, Miguel, Takács, Ferenc, Graessel, Linda, Döhner, Konstanze, Duyster, Justus, Illert, Anna Lena, Frey, Anna-Verena, Schmitt, Michael, Lübbert, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588470/
https://www.ncbi.nlm.nih.gov/pubmed/35476127
http://dx.doi.org/10.1007/s00262-022-03202-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588470/
https://www.ncbi.nlm.nih.gov/pubmed/35476127
http://dx.doi.org/10.1007/s00262-022-03202-8

Ejemplares similares